Alaunos Therapeutics Receives Formal Nasdaq Delisting Notice for Equity Deficiency
TCRT sits 73% above its 52-week low of $1.67.
Summary
Alaunos Therapeutics received a formal notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, initiating a process that could lead to delisting.
Key Events · Corporate Governance and Compliance · TCRT
-
Nasdaq Delisting Notice Received
On April 9, 2026, Alaunos Therapeutics received a formal notice from Nasdaq's Listing Qualifications Department.
-
Non-Compliance with Equity Rule
The company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. Its Annual Report on Form 10-K for fiscal year 2025 reported stockholders' equity of $2,153,000.
-
Failure to Meet Alternative Standards
Alaunos Therapeutics also fails to meet alternative continued listing standards, including a $35 million market value of listed securities or $500,000 in net income.
-
Deadline for Compliance Plan
The company has 45 calendar days (until May 26, 2026) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days.
Analysis · TCRT · Life Sciences
Alaunos Therapeutics has received a formal notice from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement, a critical development following the 'going concern' warning in its recent 10-K. The company's reported equity of $2.153 million falls below the $2.5 million minimum, alongside failing other listing standards. This formal notice escalates the delisting risk, requiring the company to submit a compliance plan within 45 days. Failure to regain compliance could lead to the suspension or delisting of its shares, posing a significant threat to investor liquidity and the company's ability to raise capital, especially given its already precarious financial position and limited cash runway into Q2 2026.
At the time of this filing, TCRT was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $1.67 to $6.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.